Last reviewed · How we verify

Vanak Eye Surgery Center — Portfolio Competitive Intelligence Brief

Vanak Eye Surgery Center pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Subconjunctival Avastin Subconjunctival Avastin phase 3 VEGF inhibitor (monoclonal antibody) VEGF (vascular endothelial growth factor) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Barnes Retina Institute · 1 shared drug class
  2. Bio-Thera Solutions · 1 shared drug class
  3. Centus Biotherapeutics Limited · 1 shared drug class
  4. Cipla BioTec Pvt. Ltd. · 1 shared drug class
  5. Eli Lilly and Company · 1 shared drug class
  6. Grewal Eye Institute · 1 shared drug class
  7. Hanny Al-Samkari, MD · 1 shared drug class
  8. Institut de Recherches Internationales Servier · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vanak Eye Surgery Center:

Cite this brief

Drug Landscape (2026). Vanak Eye Surgery Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vanak-eye-surgery-center. Accessed 2026-05-16.

Related